Will “CLINICAL PROTEOMICS” lead to the discovery of new biomarkers for dilated cardiomyopathy (DCM)?

Atkinson AJ et al (2001) Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 69(3):89–95. https://doi.org/10.1067/mcp.2001.113989 Dookhun MN, Sun Y, Zou H, Cao X, Lu X (2018) Classification of new biomarkers of dilated cardiomyopathy based on pathogenesis—an update. Health N Hav 10(03):300–312. https://doi.org/10.4236/health.2018.103024 Hershberger RE, Morales A, Siegfried JD (2010) Clinical and genetic issues in dilated cardiomyopathy: a review for genetics professionals. Genet Med 12(11):655–667. https://doi.org/10.1097/GIM.0b013e3181f2481f Japp AG, Gulati A, Cook SA, Cowie MR, Prasad SK (2016) The diagnosis and evaluation of dilated cardiomyopathy. J Am Coll Cardiol 67(25):2996–3010. https://doi.org/10.1016/j.jacc.2016.03.590 Katz SD et al (2005) Vascular endothelial dysfunction and mortality risk in patients with chronic heart failure. Circulation 111(3):310–314. https://doi.org/10.1161/01.CIR.0000153349.77489.CF Reichart D, Magnussen C, Zeller T, Blankenberg S (2019) Dilated cardiomyopathy: from epidemiologic to genetic phenotypes: a translational review of current literature. J Intern Med 286(4):362–372. https://doi.org/10.1111/JOIM.12944 Schultheiss HP et al (2019) Dilated cardiomyopathy. Nat Rev Dis Primers. https://doi.org/10.1038/s41572-019-0084-1 Sharma UC et al (2004) Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation 110(19):3121–3128. https://doi.org/10.1161/01.CIR.0000147181.65298.4D